Israel is the world leader in patents for medical devices, relative to population size, and second in the patenting of biopharm products, including pharmaceuticals and treatments.
Israel is eighth in the number of patents granted in the life-sciences industry, which may be the most amazing statistic of all, given the amount of time and money companies must invest in getting a product or technology tested and patented.
This week, the Israeli biotech industry was having its annual confer...
In 2010, the Israeli Chief Scientist approved a total of NIS 430 million in various program budgets. The R&D Committee alone considered 338 support applications from 193 companies for life science projects. 265 projects were approved for State assistance.
Statistical reports prepared by the Israeli Chief Scientist office towards the ILSI – Biomed Israel 2011 Week, which will open in Tel Aviv next week (May 23-25, 2011), show that the Chief Scientist helped support life science projects in...
Abbott Diagnostics will be attending Biomed 2011 and is interested in discussions with potential collaborators leading toward the development and commercialization of novel IA/CC biomarkers in all therapeutic areas:
o Evidence of clinical utility
o Well characterized antibody development
o Preferably, a developed ELISA format
o Workable, defendable, global IP position
The ILSI-BioMed week is closer every day. It will be opened by a keynote address by Mr. Shlomo Yanai, President and CEO of Teva, Israel.
Shlomo Yanai has been the President and Chief Executive Officer of Teva since March 2007.
Prior to joining Teva, Mr. Yanai was President and Chief Executive Officer of Makhteshim-Agan Industries Ltd. from 2003 until 2006. Previously, Mr. Yanai served in the Israel Defense Forces (the "IDF") for 32 years, where he achieved the rank of Major General, t...
ResearchPoint Global (RPG) announces its newest member, GCP Clinical Studies Ltd., a leading provider of clinical research services and educational programs in Israel. GCP conducts trials with many of the country’s top medical centers. Its educational program has assisted in establishing high quality standards throughout Israel.
"GCP is delighted and honored to be a part of the RPG organization, since this will offer our local clients the option for conducting professionally well-managed ...
How many times have you given an elevator speech that yielded NO RESULTS?
This is a Call for a Change - Don't Miss the Opportunity to Present and to Win at the upcoming 2011 ILSI - BioMed Conferenc.
Once again, BioJerusalem is delighted to hold the ‘Start Up's Pavilion’, offering start-up companies the opportunity to showcase their technologies and products. In addition, this year they offer start ups, for the first time, increased exposure with the opportunity to present your company...
May 23-25 2011. ILSI-BioMed Israel 2011, that is.
The 10th international Life Science & Technology Week is just around the corner. The event follows the highly successful 2010 BioMed conference which attracted more than 6000 participants from 51 countries.
LSI-BioMed 2011 will present high-quality program, featuring top-notch industry executives. Israel's most innovative medical device and BioPharma entrepreneurs, major pharmaceutical companies, life science research leaders, poli...
What: The Israel Conference™ encompasses a full day of inspiring global leaders, exciting company CEOs, prominent investors, and internationally recognized industry executives gathering to discuss the vitality and growth of Israel-facing business through a variety of panels on hot industry topics and trends with world-class speakers and high-quality networking. Companies are from high tech, clean tech, medical tech, consumer products, energy, security, and entertainment media technology.
Gianni Gromo is Global Head of the Metabolic & Vascular Disease Area at Roche.
He joined Roche in 1998, as Head of Global Cardiovascular Research (to include Metabolic Research from 2001) and in 2002 became Head of Discovery Research, Basel and in 2006 Head of Discovery Research and Non Clinical Development, Basel.
Before joining Roche, Gianni Gromo was Acting Vice President for the Cardiovascular Division of Eli Lilly in Indianapolis, USA, having been first Medical Advisor and then Re...